Contineum Therapeutics (CTNM) Earnings Date, Estimates & Call Transcripts $13.65 +0.35 (+2.63%) (As of 11/20/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Contineum Therapeutics Latest Earnings SummaryUpcoming Earnings DateFeb. 5EstimatedActual EPS (Nov. 6) -$0.40 Beat By $0.01 Consensus EPS (Nov. 6) -$0.41 Contineum Therapeutics posted Q3 2024 earnings on November 6, 2024, reporting an EPS of -$0.40, which topped analysts' consensus estimates of -$0.41 by $0.01. With a trailing EPS of $0.00, Contineum Therapeutics' earnings are expected to grow next year, from ($2.01) to ($1.87) per share. CTNM Upcoming EarningsContineum Therapeutics' next earnings date is estimated for Wednesday, February 5, 2025, based off prior year's reporting schedules. Get Contineum Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCTNM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CTNM Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Contineum Therapeutics Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($2.01) EPSNext Year EPS Consensus Estimate: ($1.87) EPS Contineum Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/5/2025(Estimated)------- 11/6/2024--$0.41-$0.40+$0.01-$0.40--8/13/2024--$0.37-$0.39 -$0.02-$0.39--5/16/2024Q1 2024-$0.53-$3.55 -$3.02-$3.55-- Contineum Therapeutics Earnings - Frequently Asked Questions When is Contineum Therapeutics's earnings date? Contineum Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based off last year's report dates. Learn more on CTNM's earnings history. Did Contineum Therapeutics beat their earnings estimates last quarter? In the previous quarter, Contineum Therapeutics (NASDAQ:CTNM) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.41) by $0.01. Learn more on analysts' earnings estimate vs. CTNM's actual earnings. How much revenue does Contineum Therapeutics generate each year? Contineum Therapeutics (NASDAQ:CTNM) has a recorded annual revenue of $50 million. How much profit does Contineum Therapeutics generate each year? Contineum Therapeutics (NASDAQ:CTNM) has a recorded net income of $22.72 million. CTNM has generated $0.00 earnings per share over the last four quarters. What is Contineum Therapeutics's EPS forecast for next year? Contineum Therapeutics's earnings are expected to grow from ($2.01) per share to ($1.87) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Ocular Therapeutix Earnings Results Day One Biopharmaceuticals Earnings Results Travere Therapeutics Earnings Results Praxis Precision Medicines Earnings Results Cassava Sciences Earnings Results Syndax Pharmaceuticals Earnings Results ARS Pharmaceuticals Earnings Results Arcus Biosciences Earnings Results Kura Oncology Earnings Results Gyre Therapeutics Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide This page (NASDAQ:CTNM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
